Calcitonin gene-related peptide: Novel neuropeptide

Goodman, Everard; Iversen, L. L.

doi:10.1016/0024-3205(86)90568-0

Cited by 205 publications

(62 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CGRP is a 37-amino acid peptide expressed by neurons and endocrine cells in different tissues [11]. Two isoforms of the CGRP peptide have been described: alpha-CGRP, which is formed by the alternative mRNA splicing of the calcitonin gene located on chromosome 11; and beta-CGRP, which is encoded by a different, but closely related gene [11][12][13][14][15][16][17]. Alpha-CGRP and beta-CGRP differ from each other by three amino acids in humans and by one amino acid in rats [13,15], and exhibit overlapping biological actions [16].…”

Section: Introductionmentioning

confidence: 99%

The action of CGRP and SP on cultured skin fibroblasts

Hochman

Tucci-Viegas²,

Monteiro

et al. 2014

Open Life Sciences

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

The action of CGRP and SP on cultured skin fibroblasts

Hochman

Tucci-Viegas²,

Monteiro

et al. 2014

Open Life Sciences

View full text Add to dashboard Cite

show abstract

“…Calcitonin gene-related peptide (CGRP) is a widelydistributed 37 amino acid peptide localized to peripheral sensory and motor nerves (Goodman & Iversen, 1986). CGRP, a very potent vasodilator (in part due to its direct effect on vascular smooth muscle, Brain et al, 1985;Greenberg et al, 1987), also has a number of documented actions on skeletal muscle.…”

Section: Introductionmentioning

confidence: 99%

Pharmacological characterization of a receptor for calcitonin gene‐related peptide on rat, L6 myocytes

Poyner

Andrew²,

Brown³

et al. 1992

British J Pharmacology

View full text Add to dashboard Cite

1 The L6 myocyte cell line expresses high affinity receptors for calcitonin gene-related peptide (CGRP) which are coupled to activation of adenylyl cyclase. The biochemical pharmacology of these receptors has been examined by radioligand binding or adenosine 3':5'-cyclic monophosphate (cyclic AMP) accumulation. 5 The pharmacological profile of the L6 CGRP receptor suggests that it most closely resembles sites on skeletal muscle, cardiac myocytes and hepatocytes. The L6 cell line should be a stable homogeneous model system in which to study CGRP mechanisms and pharmacology.

show abstract

“…It is known that this peptide exerts a wide variety of biological effects on various tissues, including the cardiovascular, smooth, and skeletal muscles, and endocrine and gastrointestinal systems through activation of specific plasma membrane receptor sites [38,46,47]. It is extremely important to be aware of these systemic contributions, since the administration of antagonists can affect CGRP function outside the nervous system.…”

Section: Functionmentioning

confidence: 99%

Targeting CGRP: A New Era for Migraine Treatment

Goldberg

Silberstein

2015

CNS Drugs

View full text Add to dashboard Cite

Migraine is a highly prevalent headache disease that typically affects patients during their most productive years. Despite significant progress in understanding the underlying pathophysiology of this disorder, its treatment so far continues to depend on drugs that, in their majority, were not specifically designed for this purpose. The neuropeptide calcitonin gene-related peptide (CGRP) has been indicated as playing a critical role in the central and peripheral pathways leading to a migraine attack. It is not surprising that drugs designed to specifically block its action are gaining remarkable attention from researchers in the field with, at least so far, a safe risk profile. In this article, we highlight the evolution from older traditional treatments to the innovative CGRP target drugs that are revolutionizing the way to approach this debilitating neurological disease. We provide a brief introduction on pathophysiology of migraine and details on the characteristic, function, and localization of CGRP to then focus on CGRP receptor antagonists (CGRP-RAs) and CGRP monoclonal antibodies (CGRP mAbs). Key PointsThe neuropeptide calcitonin gene-related peptide (CGRP) has been indicated as playing a critical role in the central and peripheral pathways leading to a migraine attack.Targeting CGRP as a specific therapeutic tool for migraine may offer similar or even better efficacy than currently available treatments without the vasoconstrictive risk factors.Further studies are necessary to determine the exact role of CGRP receptor antagonists and CGRP monoclonal antibodies in migraine with aura, allodynia, and photophobia.

show abstract

Calcitonin gene-related peptide: Novel neuropeptide

Cited by 205 publications

References 58 publications

The action of CGRP and SP on cultured skin fibroblasts

The action of CGRP and SP on cultured skin fibroblasts

Pharmacological characterization of a receptor for calcitonin gene‐related peptide on rat, L6 myocytes

Targeting CGRP: A New Era for Migraine Treatment

Contact Info

Product

Resources

About